CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter's five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of skin diseases
3.5.1.2.Increase in number of approval for dermatological products
3.5.1.3.Rise in awareness among individuals regarding skin diseases
3.5.2.Restraint
3.5.2.1.Availability of alternatives for acne treatment
3.5.3.Opportunities
3.5.3.1.Increase in healthcare expenditure
3.5.3.2.Development of pharmaceutical industry
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the dermatologicals market

CHAPTER 4:DERMATOLOGICALS MARKET, BY DISEASE
4.1.Overview
4.1.1.Market size and forecast
4.2.Acne
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Dermatitis
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Psoriasis
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Skin cancer
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Rosacea
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Alopecia
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Others
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:DERMATOLOGICALS MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Prescription-based drugs
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country
5.3.Over-the-counter drugs
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

CHAPTER 6:DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Topical administration
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Oral administration
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.Parenteral administration
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country

CHAPTER 7:DERMATOLOGICALS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America dermatologicals market, by disease
7.2.3.North America dermatologicals market, by type
7.2.4.North America dermatologicals market, by route of administration
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. dermatologicals market, by disease
7.2.5.1.2.U.S. dermatologicals market, by type
7.2.5.1.3.U.S. dermatologicals market, by route of administration
7.2.5.2.Canada
7.2.5.2.1.Canada dermatologicals market, by disease
7.2.5.2.2.Canada dermatologicals market, by type
7.2.5.2.3.Canada dermatologicals market, by route of administration
7.2.5.3.Mexico
7.2.5.3.1.Mexico dermatologicals market, by disease
7.2.5.3.2.Mexico dermatologicals market, by type
7.2.5.3.3.Mexico dermatologicals market, by route of administration
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe dermatologicals market, by disease
7.3.3.Europe dermatologicals market, by type
7.3.4.Europe dermatologicals market, by route of administration
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany dermatologicals market, by disease
7.3.5.1.2.Germany dermatologicals market, by type
7.3.5.1.3.Germany dermatologicals market, by route of administration
7.3.5.2.France
7.3.5.2.1.France dermatologicals market, by disease
7.3.5.2.2.France dermatologicals market, by type
7.3.5.2.3.France dermatologicals market, by route of administration
7.3.5.3.UK
7.3.5.3.1.UK dermatologicals market, by disease
7.3.5.3.2.UK dermatologicals market, by type
7.3.5.3.3.UK dermatologicals market, by route of administration
7.3.5.4.Italy
7.3.5.4.1.Italy dermatologicals market, by disease
7.3.5.4.2.Italy dermatologicals market, by type
7.3.5.4.3.Italy dermatologicals market, by route of administration
7.3.5.5.Spain
7.3.5.5.1.Spain dermatologicals market, by disease
7.3.5.5.2.Spain dermatologicals market, by type
7.3.5.5.3.Spain dermatologicals market, by route of administration
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe dermatologicals market, by disease
7.3.5.6.2.Rest of Europe dermatologicals market, by type
7.3.5.6.3.Rest of Europe dermatologicals market, by route of administration
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific dermatologicals market, by disease
7.4.3.Asia-Pacific dermatologicals market, by type
7.4.4.Asia-Pacific dermatologicals market, by route of administration
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan dermatologicals market, by disease
7.4.5.1.2.Japan dermatologicals market, by type
7.4.5.1.3.Japan dermatologicals market, by route of administration
7.4.5.2.China
7.4.5.2.1.China dermatologicals market, by disease
7.4.5.2.2.China dermatologicals market, by type
7.4.5.2.3.China dermatologicals market, by route of administration
7.4.5.3.Australia
7.4.5.3.1.Australia dermatologicals market, by disease
7.4.5.3.2.Australia dermatologicals market, by type
7.4.5.3.3.Australia dermatologicals market, by route of administration
7.4.5.4.India
7.4.5.4.1.India dermatologicals market, by disease
7.4.5.4.2.India dermatologicals market, by type
7.4.5.4.3.India dermatologicals market, by route of administration
7.4.5.5.South Korea
7.4.5.5.1.South Korea dermatologicals market, by disease
7.4.5.5.2.South Korea dermatologicals market, by type
7.4.5.5.3.South Korea dermatologicals market, by route of administration
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific dermatologicals market, by disease
7.4.5.6.2.Rest of Asia-Pacific dermatologicals market, by type
7.4.5.6.3.Rest of Asia-Pacific dermatologicals market, by route of administration
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA dermatologicals market, by disease
7.5.3.LAMEA dermatologicals market, by type
7.5.4.LAMEA dermatologicals market, by route of administration
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil dermatologicals market, by disease
7.5.5.1.2.Brazil dermatologicals market, by type
7.5.5.1.3.Brazil dermatologicals market, by route of administration
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia dermatologicals market, by disease
7.5.5.2.2.Saudi Arabia dermatologicals market, by type
7.5.5.2.3.Saudi Arabia dermatologicals market, by route of administration
7.5.5.3.South Africa
7.5.5.3.1.South Africa dermatologicals market, by disease
7.5.5.3.2.South Africa dermatologicals market, by type
7.5.5.3.3.South Africa dermatologicals market, by route of administration
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA dermatologicals market, by disease
7.5.5.4.2.Rest of LAMEA dermatologicals market, by type
7.5.5.4.3.Rest of LAMEA dermatologicals market, by route of administration

CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC. (ALLERGAN PLC)
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.AMGEN INC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.GALDERMA
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments
8.4.GLAXOSMITHKLINE PLC. (GSK)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.JOHNSON & JOHNSON SERVICES, INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.LEO PHARMA A/S
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.NOVARTIS AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.ORGANON & CO. (MERCK)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product Portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.SUN PHARMACEUTICAL INDUSTRIES LIMITED
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

List of Tables

TABLE 01.DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 02.DERMATOLOGICALS MARKET FOR ACNE, BY REGION, 2020-2030 ($MILLION)
TABLE 03.DERMATOLOGICALS MARKET FOR DERMATITIS, BY REGION, 2020-2030 ($MILLION)
TABLE 04.DERMATOLOGICALSMARKET FOR PSORIASIS , BY REGION, 2020-2030 ($MILLION)
TABLE 05.DERMATOLOGICALSMARKET FOR SKIN CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 06.DERMATOLOGICALSMARKET FOR ROSACEA, BY REGION, 2020-2030 ($MILLION)
TABLE 07.DERMATOLOGICALSMARKET FOR ALOPECIA, BY REGION, 2020-2030 ($MILLION)
TABLE 08.DERMATOLOGICALSMARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 09.DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 10.DERMATOLOGICALSMARKET FOR PRESCRIPTION-BASED DRUGS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.DERMATOLOGICALSMARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2020-2030 ($MILLION)
TABLE 12.DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 13.DERMATOLOGICALSMARKET FOR TOPICAL ADMINISTRATION, BY REGION, 2020-2030 ($MILLION)
TABLE 14.DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION , BY REGION, 2020-2030 ($MILLION)
TABLE 15.DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY REGION, 2020-2030 ($MILLION)
TABLE 16.DERMATOLOGICALS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21.U.S. DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 22.U.S. DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 23.U.S. DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 24.CANADA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 25.CANADA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 26.CANADA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 27.MEXICO DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 28.MEXICO DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 30.EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 31.EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32.EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 33.EUROPE DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34.GERMANY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 35.GERMANY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 36.GERMANY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 37.FRANCE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 38.FRANCE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 39.FRANCE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 40.UK DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 41.UK DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 42.UK DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 43.ITALY DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 44.ITALY DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 46.SPAIN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 47.SPAIN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 48.SPAIN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 49.REST OF EUROPE DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56.JAPAN DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 57.JAPAN DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 58.JAPAN DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 59.CHINA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 60.CHINA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 61.CHINA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 65.INDIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 66.INDIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 67.INDIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 68.SOUTH KOREA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 74.LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 75.LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76.LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 77.LAMEA DERMATOLOGICALS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78.BRAZIL DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 79.BRAZIL DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 80.BRAZIL DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 81.SAUDI ARABIA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 84.SOUTH AFRICA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 87.REST OF LAMEA DERMATOLOGICALS MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA DERMATOLOGICALS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION, 2020-2030 ($MILLION)
TABLE 90.ABBVIE: COMPANY SNAPSHOT
TABLE 91.ABBVIE:OPERATING SEGMENT
TABLE 92.ABBVIE: PRODUCT PORTFOLIO
TABLE 93.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94.AMGEN: COMPANY SNAPSHOT
TABLE 95.AMGEN:OPERATING SEGMENT
TABLE 96.AMGEN: PRODUCT PORTFOLIO
TABLE 97.AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.GLADERMA: COMPANY SNAPSHOT
TABLE 99.GLADERMA:OPERATING SEGMENT
TABLE 100.GLADERMA: PRODUCT PORTFOLIO
TABLE 101.GLADERMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENTS
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.J&J: COMPANY SNAPSHOT
TABLE 107.J&J: OPERATING BUSINESS SEGMENTS
TABLE 108.J&J: PRODUCT PORTFOLIO
TABLE 109.J&J: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110.LEO PHARMA: COMPANY SNAPSHOT
TABLE 111.LEO PHARMA:OPERATING SEGMENT
TABLE 112.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 113.LEO PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.NOVARTIS: COMPANY SNAPSHOT
TABLE 115.NOVARTIS: OPERATING SEGMENT
TABLE 116.NOVARTIS: PRODUCT PORTFOLIO
TABLE 117.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 118.ORGANON: COMPANY SNAPSHOT
TABLE 119.ORGANON: OPERATING SEGMENTS
TABLE 120.ORGANON: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OPERATING SEGMENTS
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125.SUN PHARMA: COMPANY SNAPSHOT
TABLE 126.SUN PHARMA: OPERATING SEGMENT
TABLE 127.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 128.SUN PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS

List of Figures

FIGURE 01.GLOBAL DERMATOLOGICALS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ACNE, BY COUNTRY, 2020-2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR DERMATITIS, BY COUNTRY, 2020-2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PSORIASIS, BY COUNTRY, 2020-2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR SKIN CANCER, BY COUNTRY, 2020-2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ROSACEA, BY COUNTRY, 2020-2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ALOPECIA, BY COUNTRY, 2020-2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PRESCRIPTION-BASED DRUGS, BY COUNTRY, 2020-2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2020-2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020-2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020-2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF DERMATOLOGICALS MARKET FOR PARENTERAL ADMINISTRATION, BY COUNTRY, 2020-2030 (%)
FIGURE 25.ABBVIE: NET SALES, 2018-2020 ($MILLION)
FIGURE 26.ABBVIE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 27.ABBVIE: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 28.AMGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 29.AMGEN: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30.AMGEN: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31.GSK: NET SALES, 2018-2020 ($MILLION)
FIGURE 32.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.J&J: NET SALES, 2018-2020 ($MILLION)
FIGURE 35.J&J: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 36.J&J: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37.LEO PHARMA: NET SALES, 2018-2020 ($MILLION)
FIGURE 38.LEO PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 39.LEO PHARMA: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 41.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 42.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 43.ORGANON: REVENUE, 2018-2020 ($MILLION)
FIGURE 44.ORGANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.ORGANON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 46.PFIZER: REVENUE, 2018-2020 ($MILLION)
FIGURE 47.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 48.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 49.SUN PHARMA: NET SALES, 2018-2020 ($MILLION)
FIGURE 50.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.SUN PHARMA: REVENUE SHARE, BY REGION, 2020 (%)

Companies Mentioned
AbbVie Inc.(Allergan PLC).
Amgen Inc.
Galderma
GlaxoSmithKline Plc.
Johnson & Johnson Services Inc
Leo Pharma A/S
Novartis AG
Organon & Co (Merck)
Pfizer Inc.
Sun Pharmaceutical Industries Limited.